MARKET WIREReuters • 2h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why IMDX Stock Traded Steady Today — RQD Quant Desk Flash
$3.18 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $3.17
Insight Molecular Diagnostics Inc. (IMDX) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $104.1M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $3.17 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMDX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY IMDX SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (35% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$3.37-10.7% Next Q
39
Q2 (-2Q)Grade E$3.01-6% Next Q
36
Q3 (-1Q)Grade E$2.83+12.4% Next Q
34
CurrentGrade E$3.18-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMDX Turnaround Squeeze
While IMDX currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.62) and Max Pain ($3.34) forces dealer call-delta covering toward $8.94.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMDX Stock Traded Steady Today — RQD Quant Desk Flash
Insight Molecular Diagnostics Inc. (IMDX) slipped 0.00% to $3.18, trading at 12% of its 52-week range ($2.42 – $8.51). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 12% of its 52-week range ($2.42 – $8.51) with RSI-14 at 41.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $3.18 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 56.7% gross margin and $0 annual free cash flow.
Live IMDX Headlines & Catalysts
MARKET WIRECNBC • 4h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 4h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 5h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 7h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 8h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 8h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMDX)
- ✓Walkthrough of IMDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -20.70%⚡ TESTING RESISTANCE
2026-10-30O $3.12H $3.18L $2.95C $3.18VOL 62.0K
RES: $3.39SUP: $2.35SMA50: $3.62SMA200: $4.73
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +115.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IMDX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMDX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMDX)
Health Care Rank #927 of 1016
⚔️ ICCC vs IMDX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMDX vs. ICCC, TKNO, NNNN, MYGN)
Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Insight Molecular Diagnostics Inc. (IMDX) ranks #927 by composite RQD confidence (31/100, grade E) and #657 by equity capitalization ($104.1M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. ICCC currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with IMDX at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMDX
ACTIVE
Insight Molecular Diagnostics Inc. | E | 31/100 | — | 56.7% | -35.0% | 0.00% | $104.1M | Benchmark Subject |
| ICCC ImmuCell Corporation | D | 50/100 | — | 41.4% | 4.2% | -2.82% | $93.7M | /iccc-vs-imdx → |
| TKNO Alpha Teknova Inc. | D | 44/100 | — | 33.2% | -21.3% | +2.93% | $499.2M | /tkno-vs-imdx → |
| NNNN Anbio Biotechnology (Class A) | D | 45/100 | 83.6x | 87.2% | 17.0% | -3.12% | $535.3M | /nnnn-vs-imdx → |
| MYGN Myriad Genetics Inc. | D- | 39/100 | — | 69.9% | -35.0% | +0.60% | $638.0M | /mygn-vs-imdx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001642380In its most recent audited fiscal period (FY2025, filed 2025-12-31), Insight Molecular Diagnostics Inc. (IMDX) reported GAAP revenue of $4.1M (+115.6% vs. FY2024 revenue of $1.9M , and +169.8% cumulative change since FY2023) , GAAP net income of -$50.2K, operating cash flow of -$22.2M, and free cash flow of -$25.4M (-19.6% YoY). On the balance sheet, IMDX closed FY2025 with $25.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $4.1M | -$50.2K | -$22.2M | -$25.4M | $25.8M | — |
| FY2024 (FY) | 2024-12-31 | $1.9M | -$60.7K | -$20.7M | -$21.2M | $35.1M | — |
| FY2023 (FY) | 2023-12-31 | $1.5M | -$27.8K | -$23.3M | -$23.3M | — | — |
3. IMDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.18 (0.00% 1D, market cap $104.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMDX ranks #927 in composite RQD confidence.
How does IMDX compare to ICCC and TKNO in the Health Care sector?
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), IMDX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 56.7%, and ROIC of -35.0%. By comparison, ICCC (ImmuCell Corporation) holds a D grade (50/100 RQD, P/E N/A, ROIC 4.2%, cap $93.7M) and TKNO (Alpha Teknova Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -21.3%, cap $499.2M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMDX?
Per IMDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001642380), Insight Molecular Diagnostics Inc. generated $4.1M in revenue (+115.6% YoY), -$50.2K in net income, and -$25.4M in free cash flow against $25.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMDX trading relative to its 50-day, 200-day, and 52-week technical levels?
IMDX last traded at $3.18 (0.00% on volume of 111,912 shares), positioning the stock -12.15% below its 50-day simple moving average ($3.62) and -32.77% below its 200-day simple moving average ($4.73). Across its 52-week range of $2.42 to $8.51, IMDX sits at the 12.5% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.78 to $3.58).
IMDX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IMDX stock moving today?
Why IMDX Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.